Streetbeat News

Price Targets

MELI

Analysts have varied opinions on MercadoLibre (NASDAQ:MELI), with most being bullish or somewhat bullish. The average 12-month price target has increased by 10.91% to $2388.44. MercadoLibre shows strong financial performance with high revenue growth, net margin, ROE, and ROA.

Portfolio Pulse from Benzinga Insights

October 11, 2024 | 12:00 pm

CPT

Jefferies has initiated coverage on Camden Property Trust (NYSE:CPT) with a Hold rating and set a price target of $123.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 12:00 pm

CPT

Camden Property Trust (NYSE:CPT) has received mixed analyst ratings over the past three months, with a majority being indifferent. Recent price targets show an upward trend, with an average target of $124.47, reflecting an 11.19% increase from the previous average. Camden's financials show strong net margins and ROE, but revenue growth lags behind industry peers.

Portfolio Pulse from Benzinga Insights

October 11, 2024 | 12:00 pm

EWTX

Piper Sandler analyst Yasmeen Rahimi has maintained an Overweight rating on Edgewise Therapeutics (NASDAQ:EWTX) and raised the price target from $48 to $51.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 11:28 am

CMG

Piper Sandler analyst Brian Mullan maintains a Neutral rating on Chipotle Mexican Grill (NYSE:CMG) and raises the price target from $56 to $59.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 11:26 am

VFC

Goldman Sachs analyst Brooke Roach has reinstated a Neutral rating on VF Corporation (NYSE:VFC) and set a price target of $20.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 11:20 am

KMI

B of A Securities has upgraded Kinder Morgan (NYSE:KMI) from Neutral to Buy, raising the price target from $23 to $27.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 11:17 am

EBAY

Baird analyst Colin Sebastian maintains an Outperform rating on eBay and raises the price target from $62 to $70.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 11:15 am

DRTS

HC Wainwright & Co. has reiterated its Buy rating on Alpha Tau Medical (NASDAQ:DRTS) and maintained a price target of $9.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 10:54 am

MIRM

HC Wainwright & Co. analyst Ed Arce has reiterated a Buy rating for Mirum Pharmaceuticals, maintaining a price target of $66.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 10:47 am